Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded… Read more
Pure Biologics Spólka Akcyjna (PUR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.011x
Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) has a cash flow conversion efficiency ratio of 0.011x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-216.00K) by net assets (zł-19.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pure Biologics Spólka Akcyjna - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Pure Biologics Spólka Akcyjna's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pure Biologics Spólka Akcyjna Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pure Biologics Spólka Akcyjna ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hayasa Metals Inc.
V:HAY
|
-0.252x |
|
Richy Place 2002 Public Company Limited
BK:RICHY
|
0.031x |
|
Sulliden Minerals SA
TO:SMC
|
0.090x |
|
MODIVCARE INC. DL-001
F:PRF0
|
N/A |
|
Magnasense AB
ST:MAGNA
|
N/A |
|
GMP Property SOCIMI SA
MC:YGMP
|
0.013x |
|
Banka BioLoo Limited
NSE:BANKA
|
0.140x |
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
-0.771x |
Annual Cash Flow Conversion Efficiency for Pure Biologics Spólka Akcyjna (2016–2024)
The table below shows the annual cash flow conversion efficiency of Pure Biologics Spólka Akcyjna from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł-13.12 Million | zł-10.83 Million | 0.826x | +106.72% |
| 2023-12-31 | zł1.89 Million | zł-23.26 Million | -12.288x | -1193.16% |
| 2022-12-31 | zł18.30 Million | zł-17.39 Million | -0.950x | -56.11% |
| 2021-12-31 | zł39.49 Million | zł-24.04 Million | -0.609x | -229.88% |
| 2020-12-31 | zł-2.89 Million | zł-1.35 Million | 0.469x | -36.63% |
| 2019-12-31 | zł7.21 Million | zł5.33 Million | 0.740x | +166.02% |
| 2018-12-31 | zł2.22 Million | zł-2.49 Million | -1.120x | +91.75% |
| 2017-12-31 | zł209.77K | zł-2.85 Million | -13.583x | -496.09% |
| 2016-12-31 | zł311.70K | zł-710.24K | -2.279x | -- |